FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileBone Biologics Corporation
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
BBLGW
Bone Biologics Corporation Stock AnalysisComprehensive stock analysis for Bone Biologics Corporation (BBLGW) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisBBLGW
BBLGW
Bone Biologics Corporation
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
BBLGW
  1. Home
  2. Stocks
  3. Bone Biologics Corporation

Bone Biologics Corporation

🇺🇸BBLGW•NASDAQ

Bone Biologics Corporation

🇺🇸BBLGW•NASDAQ
Market cap
$1.47M

Your view on BBLGW

Mkt Cap
$1.47M
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Bone Biologics Corporation

Industry
Biotechnology
Sector
Healthcare
CEO
Jeffrey Frelick
Headquarters
2 Burlington Woods Drive, Burlington, MA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Jeffrey Frelick
Headquarters
2 Burlington Woods Drive, Burlington, MA, US
Description

Bone Biologics Corporation is a medical device firm dedicated to revolutionizing bone regeneration, particularly within spinal fusion procedures. The company's primary innovation is NELL-1/DBX, a unique combination product featuring an osteostimulative recombinant protein.

This bio-engineered protein offers precise, targeted control over new bone formation. Currently, Bone Biologics is advancing the NELL-1/DBX Fusion Device, specifically engineered for spinal fusion applications in skeletally mature patients suffering from degenerative disc disease, focusing on single-level fusions from L4 to S1.

Beyond spinal applications, the versatility of its foundational technology promises to deliver improved outcomes across various surgical disciplines, including general orthopedics, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.

Underpinning its development, the company holds a licensing agreement with the UCLA Technology Development Group to further develop and commercialize NELL-1 for spinal fusion. Established in 2004, Bone Biologics Corporation is headquartered in Burlington, Massachusetts.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Bone Biologics Corporation. Starting points for Bone Biologics Corporation: EPS -$0.76, beta 0.53 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Bone Biologics Corporation. Trailing twelve-month EPS for Bone Biologics Corporation stands at -$0.76. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 22, 2026
More →

Earnings per share estimates

Per shareThis quarterDec 2026This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate−$0.18−$1.23−$0.67
Lowest estimate−$0.18−$1.23−$0.67
Highest estimate−$0.18−$1.23−$0.67
Number of analysts111
A year ago−$0.581−$2.651—
Growth vs a year ago———

1The year-ago figure includes one-time items, so growth is not shown.

Revenue estimates

TotalThis quarterDec 2026This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate$0.00$0.00$0.00
Lowest estimate$0.00$0.00$0.00
Highest estimate$0.00$0.00$0.00
Number of analysts000
A year ago$0.00$0.00—
Growth vs a year ago———

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Bone Biologics Corporation. Bone Biologics Corporation has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold BBLGW19 companies
Compare BBLGW with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustryMkt cap
AMIXAutonomix Medical, Inc. Common StockHealthcareMedical - Devices$484,136
BGMSBio Green Med Solution, Inc.HealthcareMedical - Pharmaceuticals$3.1M
CNSPCNS Pharmaceuticals, Inc.HealthcareBiotechnology$5.3M
DHAIDIH Holding US, Inc.HealthcareMedical - Devices—
HSCSHeartSciences Inc.HealthcareMedical - Devices$9.0M
MOVEMovano Inc.HealthcareMedical - Devices$103.2M
RDHLRedHill Biopharma Ltd.HealthcareDrug Manufacturers - Specialty & Generic$883,143
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
BVNRYBavarian Nordic A/SHealthcareOTC$2.4B
BXPHFBotanix Pharmaceuticals LimitedHealthcareOTC$89.0M
ARUXFAcrux LimitedHealthcareOTC$1.8M
ARVNArvinas, Inc.HealthcareNASDAQ$423.0M
ARWRArrowhead Pharmaceuticals, Inc.HealthcareNASDAQ$5.8B
ASBPAspire Biopharma Holdings, Inc.HealthcareNASDAQ$822,602
ASBPWAspire Biopharma Holdings, Inc.HealthcareNASDAQ$121,920
ASCLFAscletis Pharma Inc.HealthcareOTC$2.1B
ASEP.CNAsep Medical Holdings IncHealthcareCNQ—
ASMBAssembly Biosciences, Inc.HealthcareNASDAQ$454.4M
ASNDAscendis Pharma A/SHealthcareNASDAQ$16.6B
ASPEAspen Neuroscience Inc.HealthcareNASDAQ$361.2M
Open Comparable Analysis
Ownership & News

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Bone Biologics Corporation executives and directors. Shares of Bone Biologics Corporation have traded between $6.80 and $35.95 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Bone Biologics Corporation. Coverage tracks Bone Biologics Corporation within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Bone Biologics Corporation.

BBLGW AnalysisFair
Past
1
Growth
2
Health
5
Profit
1
Value
1